title: Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal.
abstract: Cancer anorexia-cachexia syndrome (CACS) is a combination of anorexia, tissue wasting, weight loss and poor performance status. Some CACS symptoms are due to a macrophage production of TNF and IL-1, while the metabolic effects are mainly explained by the release of IL-6 from tumor cells. Clinical treatment of CACS involves progestational agents (medroxyprogesterone acetate, MPA, megestrol acetate, MA) for long term treatment. The use of prokinetic agents (like metoclopramide) is recommended, especially if patients need concomitant opioid treatment for pain; if otherwise indicated, corticosteroids are useful for short periods. The administration of artificial nutrition should be individualized following the clinical condition of the patient and possibly taking into account the wishes of the patient. The practical evaluation criteria of the drugs employed for CACS are based on weight increase and appetite stimulation. Hence, a new approach to the mechanism of action of MPA, MA and of other agents is urgently needed.
authors.affiliation: Clinical Oncology Unit, Department of Oncology-Pathology, Azienda Ospedaliera Universitaria, Ferrara, Italy. g.lelli@ospfe.it
authors.forename: G
authors.initials: G
authors.lastname: Lelli
authors.forename: M
authors.initials: M
authors.lastname: Montanari
authors.forename: G
authors.initials: G
authors.lastname: Gilli
authors.forename: D
authors.initials: D
authors.lastname: Scapoli
authors.forename: C
authors.initials: C
authors.lastname: Antonietti
authors.forename: D
authors.initials: D
authors.lastname: Scapoli
mesh_terms: D000855:Anorexia / Q000188:drug therapy / Q000209:etiology; D002100:Cachexia / Q000188:drug therapy / Q000209:etiology; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D019290:Megestrol Acetate / Q000008:administration & dosage*; D008787:Metoclopramide / Q000008:administration & dosage*; D009369:Neoplasms / Q000150:complications*; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis; D019452:Terminally Ill; D016896:Treatment Outcome; D019282:Wasting Syndrome / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality
chemical_list: D017258:Medroxyprogesterone Acetate; D008787:Metoclopramide; D019290:Megestrol Acetate